Predicting Preeclampsia With a Protein? Gene-Silencing for Cardiomyopathy
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
In this week's TTHealthWatch podcast, Elizabeth Tracey and Rick Lange discuss several medical headlines from Texas Tech University Health Sciences Center in El Paso. They begin by discussing the establishment of the Vaccine Integrity Project by the American Medical Association, which aims to provide a trusted voice in vaccine-related information amidst ongoing controversies.
The project evaluates the efficacy, benefits, side effects, and recommendations for COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines. COVID-19 vaccines have been shown to reduce the risk of severe disease, hospital encounters, and death across multiple age and risk groups, with vaccine efficacy ranging from 20% to 55% against COVID-related hospitalization.
Influenza vaccine efficacy ranges from 19% to 43%, reducing mortality by 30% to nearly 66%, and maternal vaccination reduces the risk of symptomatic disease in infants by over 44%. RSV vaccines have shown efficacy in reducing infant RSV-related hospitalization ranging from 51% to 70%. The discussion then shifts to gene-silencing therapy for transthyretin amyloid cardiomyopathy, a condition caused by misfolded proteins accumulating in the heart. The therapy aims to prevent the production of the harmful protein altogether.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
